Quick Takeaways
- Almitas Capital LLC filed SCHEDULE 13G for AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX).
- Disclosed ownership: 5.4%.
- Date of event: 31 Dec 2025.
Almitas Capital LLC - 31 Dec 2025 SCHEDULE 13G Report for AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX)
- Filing Manager
- Almitas Capital LLC
- Reporting Manager
- Almitas Capital LLC
- Symbol
- ANTX
- Shares outstanding
- 55,095,630 shares
- Disclosed Ownership
- 2,975,164 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Feb 2026, 18:54:12 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Almitas Capital LLC disclosed 5.4% ownership in AN2 Therapeutics, Inc. Common Stock and Warrants (ANTX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 18:54.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Almitas Capital LLC | 5.4% | 2,975,164 | 2,975,164 | 0 | Ronald Mass | Managing Principle |